Achieve Scalable and High Recovery in rAAV Harvest Process

Published on: 


Webinar Date/Time: Wed, Jun 19, 2024 11:00 AM EDT

See the research behind an effective cell lysis alternative that is biodegradable, scalable, and sustainable.

Register Free:

Event Overview:

Chemical lysis has become the preferred harvest method in viral gene therapy manufacturing due to scalability and consistency, yet new challenges have emerged that current cell lysis reagents fail to address. Namely, Triton X-100 is listed as a substance of very high concern by the European Chemicals Agency. There are also issues with reagent volume usage, high viscosity, and foaming, and inadequate protection of the viral vector from damage during processing.

This webinar will offer research illustrating key performance benefits of a novel biodegradable cell lysis solution when paired with a quality endonuclease. This solution shows improved protection of particles during agitation, as well as flexible process development with a ready-to-use formula that reduces foaming and viscosity and allows for room temperature storage and shipping.

Key Learning Objectives:

  • Identify challenges of chemical lysis in the current regulatory landscape and at scale
  • Discuss the development process of a novel cell lysis solution to address these challenges
  • Review research results illustrating performance benefits and industry case studies

Who Should Attend:

  • Process development engineers or scientists
  • MSAT engineers
  • New technology or innovation scientists
  • R&D and early discovery scientists
  • Raw materials managers


Jungmin Oh, PhD
Manager, New Product Development

Jungmin Oh, PhD, is a manager of the new product development group at Avantor in its Innovation and Technology Center. In her role, she specializes in leading and developing a complete downstream process solution for biopharma customers including cell lysis solutions, viral inactivation solutions, and chromatography resin products. She joined Avantor in 2016 and has held numerous roles in R&D, focusing on product and process development, customer collaborations to support biotech research, and tech transfer. Prior to this role, she worked in optimization of downstream process for recombinant proteins including monoclonal antibodies from mammalian cells. She has contributed to the launch of J.T.Baker affinity resins with her expertise in purification process development.

Beth Kroeger-Fahnestock
Director, New Product Introduction, BioPharma

Beth Kroeger-Fahnestock is director, new product introduction, in Avantor’s biopharma production division. She currently manages new product launches to support Avantor’s mission in bringing lifesaving medicines to market. She has extensive industry experience in manufacturing, validation, technical transfer, R&D, compliance, and quality. Her areas of expertise include large-scale bioprocess systems, downstream purification operations, and process and cleaning validation, along with cleanroom environmental control. She speaks frequently on these topics for educational and professional organizations. She has served on the International Society for Pharmaceutical Engineering (ISPE) task force responsible for writing the ISPE Cleaning Validation Lifecycle – Applications, Methods, and Controls good practice guide, published in 2020. She has served as an adjunct lecturer at Temple University’s School of Pharmacy in its regulatory affairs and quality assurance graduate program for several years. She earned a bachelor of science degree in biochemistry from the University of Missouri, St Louis.

Register Free: